Skip to content
  • Follow Us

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog
  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

CarboHyde

SUGAR IS LIFE

  • Home
  • About Us
  • Pipeline
  • Technology
  • Investors and Partnering
  • Career
  • CarboHyde News
  • CarboHyde’s Blog

ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200

Jan 9, 2023Tamas Sohajdacarbohydratescholesterol, kidney disease, rare disease

ZyVersa Therapeutics Inc., developing, among others VAR200, a therapeutic 2-hydroxypropyl-beta-#cyclodextrin for FSGS, Alport syndrome, and diabetic kidney disease, just added two leading nephrologists to their Scientific Advisory Board.
We hope this will help move the program forward to follow this one-of-a-kind application of CDs with great excitement.

See the full article here

Prev
Next
Developed by Shuttle Themes. Powered by WordPress.
  • Contact Us
  • LinkedIn
  • Twitter